BNC210
Post-Traumatic Stress Disorder (PTSD)
Key Facts
About Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.
View full company profileAbout Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.
View full company profileAbout Neuphoria Therapeutics
Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.
View full company profileTherapeutic Areas
Other Post-Traumatic Stress Disorder (PTSD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| PES200 | Virpax Pharmaceuticals | Discovery/Preclinical |
| NeuroDirect™ Ketamine | Psycheceutical Bioscience | Phase 1 |
| Sana Device for PTSD | Sana Health | Pilot/Proof-of-Concept |
| MDMA-assisted therapy | Lykos Therapeutics | Phase 3 |
| Neuroplastogen Programs | Delix Therapeutics | Pre-clinical |
| TSND-201 (Methylone) | Transcend Therapeutics | Phase 2 |
| Phoenix CR | Evren Technologies | Unknown |
| Lu AG09222 | Lundbeck | Phase 2 |
| COMP360 Psilocybin Therapy | Compass Pathways | Phase 2 |
| NRX-101 | NRx Pharmaceuticals | Phase 2 |
| Ketamir-2 (Ketamir) | MIRA Pharmaceuticals | Phase 1 |